Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)
Haemophilia2019Vol. 25(5), pp. 731–737
Citations Over TimeTop 10% of 2019 papers
Sophie Susen, Yves Gruel, Anne Godiér, Annie Harroche, Hérvè Chambost, Dominique Lasne, Antoine Rauch, Stéphanie Roullet, Pierre Fontana, Jenny Goudemand, Emmanuel de Maistre, V. Chamouard, B. Wibaut, Pierre Albaladejo, Claude Négrier
Abstract
The lack of data means that it is only possible to issue proposals rather than recommendations.
Related Papers
- → The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey(2008)94 cited
- → Inhibitors in the Swedish population with severe haemophilia A and B: a 20‐year survey(2002)32 cited
- → Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey(2002)28 cited
- [Haemophilia].(2014)
- → Genetic-Epidemiologic Study of Haemophilia A and B in Hungary(1990)9 cited